Biora Therapeutics, Inc. has updated its prospectus supplement, which now supersedes certain information from the original prospectus dated December 29, 2023. The update pertains to the offering of a significant number of shares of common stock related to various financial instruments. Specifically, the offering includes shares issuable upon conversion of convertible senior secured notes due in 2028, shares potentially issuable for interest payments or make-whole amounts on these notes, and shares issuable upon the exercise of different sets of warrants with varying exercise prices and terms. Additionally, Biora Therapeutics has entered into a Warrant Amendment Agreement on March 31, 2024, with an institutional investor to amend the terms of the Commitment Warrants. The amendments include a reduction in the exercise price to $1.10 per share...Show More

Biora Therapeutics, Inc. has updated its prospectus supplement, which now supersedes certain information from the original prospectus dated December 29, 2023. The update pertains to the offering of a significant number of shares of common stock related to various financial instruments. Specifically, the offering includes shares issuable upon conversion of convertible senior secured notes due in 2028, shares potentially issuable for interest payments or make-whole amounts on these notes, and shares issuable upon the exercise of different sets of warrants with varying exercise prices and terms. Additionally, Biora Therapeutics has entered into a Warrant Amendment Agreement on March 31, 2024, with an institutional investor to amend the terms of the Commitment Warrants. The amendments include a reduction in the exercise price to $1.10 per share, a condition that the warrants cannot be exercised until stockholder approval is received, and an extension of the expiration date to five years post-approval. The company's common stock is traded on the Nasdaq Global Market under the symbol 'BIOR', and as of March 28, 2024, the stock was valued at $1.10 per share. The prospectus supplement, dated April 2, 2024, advises investors of the high degree of risk involved in investing in these securities.